Daniel Ernesto Lawrence

Author:

Daniel Lawrence

ISBN #:

0521098475

Author:

Daniel Lawrence

ISBN #:

0521203538

Author:

Daniel Lawrence

ISBN #:

0595355005

Author:

Daniel Lawrence

ISBN #:

0751200573

Address:

109 Willowbay Rdg St, Sanford, FL 32771

VIN:

1G6DM57T970161818

Make:

CADILLAC

Model:

CTS

Year:

2007

US Patent:

6489143, Dec 3, 2002

Filed:

Jun 2, 1999

Appl. No.:

09/324494

Inventors:

Daniel A. Lawrence - Derwood MD
Steingrimur P. Stefansson - Gaitherburg MD

Assignee:

American National Red Cross - Falls Church VA

International Classification:

C12N 1509

US Classification:

435 692, 435440, 435471, 435218, 435325, 4352523, 536 231, 536 235

Abstract:

Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at positions 331 and 346 of the mature protein. These mutants are notable in being resistant to inactivation by elastase, having high affinity for Vn, or both properties. These mutant proteins as pharmaceutical compositions are used to inhibit elastase in a subject, thereby treating a number of disorders associated with elastase activity, most notably emphysema, ARDS, inflammatory lung injury and cystic fibrosis. The mutants which interact with Vn are used to inhibit cell migration in a subject, thereby treating diseases or conditions associated with undesired cell migration and proliferation, particularly of smooth muscle cells. Such conditions include atherosclerosis, post angioplasty restenosis, fibrosis associated with chronic inflammation or chemotherapy, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. Also disclosed are peptides of such mutant proteins, mutant-specific antibodies, nucleic acid molecules, particularly DNA, encoding the mutant protein and host cells transformed by such nucleic acids.

US Patent:

7087574, Aug 8, 2006

Filed:

Jan 31, 2003

Appl. No.:

10/355208

Inventors:

Daniel A. Lawrence - Derwood MD, US
Manuel Yepes - Alexandria VA, US
Maria Sandkvist - Derwood MD, US
Timothy A. Coleman - Gaithersburg MD, US
Michael K. K. Wong - Wexford PA, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD
The American Red Cross - Falls Church VA

International Classification:

A61K 38/57
A61K 39/00
C07K 14/47
C12P 21/06

US Classification:

514 12, 514 2, 530350, 4241921, 435 691

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.

US Patent:

7235529, Jun 26, 2007

Filed:

Jan 7, 2004

Appl. No.:

10/752041

Inventors:

Timothy A. Coleman - Gaithersburg MD, US
Daniel A. Lawrence - Derwood MD, US
Manuel Yepes - Alexandria VA, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD
The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 38/57
A61K 39/00
C07K 14/47
C12P 21/06

US Classification:

514 12, 514 2, 530350, 4241921, 4241841, 4241851, 435 691

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.

US Patent:

7264953, Sep 4, 2007

Filed:

Jul 18, 2002

Appl. No.:

10/197258

Inventors:

Daniel A. Lawrence - Derwood MD, US
Natalia Gorlatova - Rockville MD, US
David L. Crandall - Doylestown PA, US

Assignee:

American National Red Cross - Falls Church VA
Wyeth - Madison NJ

International Classification:

C12N 9/99

US Classification:

435184

Abstract:

A library of mutants of metastable proteins, such as proteinase inhibitors, can be screened for the specific loss of a wild-type capability to bind an antibody, yielding valuable drug-design information which otherwise is unavailable. By this approach, for example, a mutant proteinase inhibitor can be obtained that has the amino acid sequence of a wild-type protein, or an active fragment thereof, save for the presence of one or more mutations in at least one epitope, thereby altering interaction of the mutant with an anti-proteinase inhibitor antibody.

US Patent:

7375076, May 20, 2008

Filed:

May 20, 2004

Appl. No.:

10/849540

Inventors:

Daniel A. Lawrence - Derwood MD, US
Manuel S. Yepes - Rockville MD, US
Dudley Strickland - Brookeville MD, US

Assignee:

The Regents of The University of Michigan - Ann Arbor MI

International Classification:

A61K 38/00

US Classification:

514 2

Abstract:

The present invention is a method of reducing vascular permeability in tissue of a subject comprising inhibiting the activity of serine proteinase tissue-type plasminogen activator (tPA). This tPA activity which increases permeability of the tissue in a subject results in edema in the tissue is separate from tPA's thrombolytic activity. The present invention more specifically relates to administering an amount of a tPA inhibitor sufficient to reduce the vascular permeability increasing activity of tPA in a subject. Useful tPA inhibitors for the present method are neuroserpin, mutant neuroserpin, wild-type PAI-1, mutant PAI-1, an antibody that binds to tPA, an antibody that binds to the low-density lipoprotein (LDL) receptor or a low-density lipoprotein (LDL) receptor family antagonist.

US Patent:

7388074, Jun 17, 2008

Filed:

Sep 30, 2002

Appl. No.:

10/259609

Inventors:

Daniel A. Lawrence - Derwood MD, US

Assignee:

The Regents of The University of Michigan - Ann Arbor MI

International Classification:

A61K 38/00

US Classification:

530350, 514 2

Abstract:

Mutants of the human PAI-1 protein are described which are inhibitors of neutrophil elastase or are inhibitors of vitronectin (Vn)-dependent cell migration. These mutants preferably comprise one or two amino acid substitutions in the reactive center loop of PAI-1, particularly at positions 331 and 346 of the mature protein. These mutants are notable in being resistant to inactivation by elastase, having high affinity for Vn, or both properties. These mutant proteins as pharmaceutical compositions are used to inhibit elastase in a subject, thereby treating a number of disorders associated with elastase activity, most notatably emphysema, ARDS, inflammatory lung injury and cystic fibrosis. The mutants which interact with Vn are used to inhibit cell migration in a subject, thereby treating diseases or conditions associated with undesired cell migration and proliferation, particularly of smooth muscle cells. Such conditions include atherosclerosis, post angioplasty restenosis, fibrosis associated with chronic inflammation or chemotherapy, tumor invasion and metastasis and conditions in which angiogenesis is pathogenic. Also disclosed are peptides of such mutant proteins, mutant-specific antibodies, nucleic acid molecules, particularly DNA, encoding the mutant protein and host cells transformed by such nucleic acids.

US Patent:

20020143165, Oct 3, 2002

Filed:

Sep 21, 2001

Appl. No.:

09/957485

Inventors:

Daniel Lawrence - Derwood MD, US
Manuel Yepes - Alexandria VA, US
Maria Sandkvist - Derwood MD, US
Michael Wong - Wexford PA, US
Timothy Coleman - Gaithersburg MD, US

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

C07H021/02
C07H021/04

US Classification:

536/023100

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had a stroke.

US Patent:

20020165147, Nov 7, 2002

Filed:

Nov 13, 2001

Appl. No.:

09/987021

Inventors:

Manuel Yepes - Alexandria VA, US
Daniel Lawrence - Derwood MD, US
Timothy Coleman - Gaithersburg MD, US

International Classification:

A61K038/17
C07H021/04
C12P021/02
C12N005/06
C07K014/435

US Classification:

514/012000, 530/350000, 536/023500, 435/069100, 435/320100, 435/325000

Abstract:

The present invention relates to a novel BAIT protein which is a member of serpin superfamily which is expressed primarily in brain tissue. In particular, isolated nucleic acid molecules are provided encoding the human and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of BAIT activity. Also provided are diagnostic methods for detecting nervous system-related disorders and therapeutic methods for treating nervous system-related disorders. Additionally, the present invention is related to methods of treating patients with BAIT polynucleotides or polypeptides, wherein said patients have had seizures or epilepsy.